Difference between revisions of "Dalpiciclib (SHR-6390)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/dalpiciclib NCI Drug Dictionary]: A cyclin-dependent kinase (CDK) inhibitor with...") |
|||
| Line 3: | Line 3: | ||
==Preliminary data== | ==Preliminary data== | ||
| − | ===[[Breast cancer]]=== | + | ===[[Breast cancer, ER-positive]]=== |
*'''DAWNA-1:''' NCT03927456 | *'''DAWNA-1:''' NCT03927456 | ||
Revision as of 20:58, 4 June 2021
Mechanism of action
From NCI Drug Dictionary: A cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Upon administration, dalpiciclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6). This inhibits retinoblastoma (Rb) protein phosphorylation early in the G1 phase, which prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation.
Preliminary data
Breast cancer, ER-positive
- DAWNA-1: NCT03927456
Also known as
- Code name: SHR6390